HC Wainwright Has Negative Estimate for VTYX FY2029 Earnings

Ventyx Biosciences, Inc. (NASDAQ:VTYX) – Research analysts at HC Wainwright cut their FY2029 earnings per share (EPS) estimates for Ventyx Biosciences in a research note issued on Thursday, January 8th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.57) per share for the year, down from their previous forecast of ($1.50). HC Wainwright has a “Neutral” rating and a $14.00 price objective on the stock. The consensus estimate for Ventyx Biosciences’ current full-year earnings is ($2.09) per share.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13.

VTYX has been the topic of several other reports. Oppenheimer downgraded shares of Ventyx Biosciences from an “outperform” rating to a “market perform” rating in a research report on Thursday. Lifesci Capital reissued a “market perform” rating and set a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday. UBS Group restated a “neutral” rating and issued a $14.00 price target (down previously from $20.00) on shares of Ventyx Biosciences in a research report on Thursday. Canaccord Genuity Group downgraded Ventyx Biosciences from a “buy” rating to a “hold” rating and reduced their price objective for the company from $16.00 to $14.00 in a research note on Thursday. Finally, Clear Str cut Ventyx Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 7th. Eight research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Ventyx Biosciences has an average rating of “Reduce” and a consensus target price of $14.86.

Ventyx Biosciences Price Performance

VTYX stock opened at $13.81 on Monday. The company has a market cap of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23. The company has a fifty day moving average price of $9.27 and a 200 day moving average price of $5.32. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $25.00.

Institutional Trading of Ventyx Biosciences

Several hedge funds have recently modified their holdings of VTYX. CWM LLC boosted its stake in shares of Ventyx Biosciences by 7.6% during the 2nd quarter. CWM LLC now owns 57,145 shares of the company’s stock worth $122,000 after purchasing an additional 4,057 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Ventyx Biosciences by 21.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock valued at $62,000 after buying an additional 5,174 shares during the last quarter. Prelude Capital Management LLC raised its position in shares of Ventyx Biosciences by 35.0% in the third quarter. Prelude Capital Management LLC now owns 21,200 shares of the company’s stock valued at $66,000 after buying an additional 5,500 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Ventyx Biosciences during the third quarter worth approximately $51,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Ventyx Biosciences

In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 18.18% of the company’s stock.

Trending Headlines about Ventyx Biosciences

Here are the key news stories impacting Ventyx Biosciences this week:

• Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences
• Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported
• Neutral Sentiment: Wells Fargo reaffirmed an “equal weight” rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note
• Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to “market perform”/”hold” around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage
• Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgrade Canaccord downgrade
• Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick & Foti investigation Edelson Lechtzin investigation

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.